Clinical Trials Browser

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06184867 2026-03-06

CATALYST

Phase NA Completed

50 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05035173 2026-03-04

LYSA

Phase NA Completed

200 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Gynecologic

Endometrial Neoplasms

NCT07250178 2026-01-07

ONSD as an ICP Marker in vNOTES and TLH

Phase NA Completed

66 enrolled

Gynecologic

Metrorrhagia, Endometrial Neoplasms, Myofibroma

NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Phase 1 Completed

40 enrolled

BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06846099 2025-12-23

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

Phase 1 Completed

69 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03027479 2025-12-22

METERMUS-IMC

Phase NA Completed

70 enrolled

GynecologicOther

Obesity, Ovarian Neoplasms, Weight Loss, Endometrial Neoplasms

Clinical Trials

MiGHT

CATALYST

LYSA

LEAP-001

ONSD as an ICP Marker in vNOTES and TLH

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

METERMUS-IMC